Chemed Insider Buy Signals Confidence, Not Panic – VP Purchases 351 Shares Amid $300 M Buy‑Back

Insider Activity Signals Confidence, Not Panic

Chemed Corp’s most recent insider‑trading disclosure, filed on 13 February 2026, reveals that Vice President and Chief Legal Officer Brian Judkins purchased 351 shares of the company’s capital stock at $469.56 per share. The transaction brought Judkins’ post‑purchase holding to 2,538 shares. The acquisition followed the vesting of performance‑stock units (PSUs) that surpassed Chemed’s earnings targets for the 2023‑2025 period, thereby confirming that the board’s incentive plan is functioning as intended. This move aligns with Chemed’s broader shareholder‑return strategy, which includes a recently approved $300 million share‑buyback program and the payment of a $0.60 quarterly dividend. Together, these actions signal management’s confidence in the company’s future cash‑flow generation.

Market Context

The purchase was executed on a day when Chemed’s share price was flat at $475.09, after a 6 % weekly gain and a positive sentiment score of +18 across 39 % of social‑media mentions. Although the dollar amount of the trade is modest, its symbolic weight is amplified by the surrounding conditions:

The combination of a stable price, bullish sentiment, and an insider purchase can reinforce positive expectations among investors. At the same time, the company’s year‑to‑date decline of 14.5 % and a price‑to‑earnings ratio of 24.96 suggest that valuation remains a concern for more cautious participants. Chemed’s diversified service portfolio—including health care, plumbing, and restoration—may help mitigate sector‑specific volatility, but sustained earnings growth will be essential to justify the current valuation.

Judkins’ Long‑Term Investment Pattern

Historically, Judkins has been a steady buyer of Chemed shares. His most recent purchase of 15,017 shares on 21 October 2025 at $443.79 per share increased his cumulative holdings from 38,067 to 2,538 shares in the latest transaction, reflecting a disciplined approach to equity participation. Unlike some executives who frequently offload shares during earnings seasons, Judkins has rarely sold. The February 2026 transaction also involved the sale of 102 shares to satisfy tax obligations related to PSUs, a routine tax‑planning maneuver. Overall, Judkins’ pattern suggests a long‑term commitment to the company’s strategic direction, reinforcing investor confidence in management’s stewardship.

Implications for Chemed’s Future

The insider buy, combined with the company’s buy‑back program, could support the share price in the short term by reducing float and signalling that insiders consider the current valuation attractive. However, investors should monitor the vesting of the new PSUs scheduled for 2026‑2028, as their eventual payout will depend on meeting ambitious performance targets. Should Chemed continue to generate strong cash flows, the dividend and buy‑back could create a virtuous cycle, attracting income‑seeking investors and potentially improving the stock’s long‑term outlook.

Transaction Summary